Amandeep Kaur

Amandeep Kaur

Auto-generated profile, based on publicly available information

Amandeep Kaur

Bridge Medical, Delhi, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2025 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
AGAdriana Guzman-Holst
Adriana Guzman-Holst
DGDigant Gupta
Digant Gupta
AKAmandeep Kaur
Amandeep Kaur
VVVikas Verma
Vikas Verma
ABArnas Berzanskis
Arnas Berzanskis
DODésirée A. M. Van Oorschot
Désirée A. M. Van Oorschot
Introduction Limited data are available on the epidemiology and clinical burden of respiratory syncytial virus (RSV) among adults with underlying medical or immunocompromising conditions (“high-risk adults”) and ≥ 50-year-old adults in developing countries. Methods To better understand the impact of RSV in these populations, a systematic literature review of articles published from the year 2000 onward reporting RSV data among high-risk 18–59-year-old adults and ≥ 50-year-old adults in low, lower-middle, upper-middle, and selected high-income countries was undertaken. Searches were run on Medical Literature Analysis and Retrieval System Online (MEDLINE) and Excerpta Medica DataBASE (EMBASE), and were supplemented by additional searches (e.g., congress abstracts, gray literature). A combination of artificial intelligence models was used for title/abstract screening. After this, full-text screening of inclusions was conducted, followed by prioritization. Results Overall, 77 citations were selected for final inclusion. Of these, 69 reported outcomes related to RSV epidemiology and clinical burden, and are reported in this article. There were limited data on RSV incidence, prevalence, disease severity, and subtype distribution. Adequate evidence was available for RSV positivity among patients with respiratory illnesses, seasonality, complications, and mortality. Incidence in ≥ 65-year-olds was in the range of ~10–178 episodes per 1000 person-years across studies. Ranges for RSV positivity among patients with different underlying respiratory conditions were 1.5–31.9% and 0–9.1%, in high-risk and ≥ 50-year-old adults, respectively. Case fatality rates of up to 15.2% and 27.0% were reported across studies for high-risk and > 60-year-old adults, respectively. Conclusions Overall, there were considerable evidence gaps for RSV epidemiology among high-risk and ≥ 50-year-old adults in developing countries. However, available data indicate a substantial negative health impact of RSV on these populations, highlighting the need for further data generation.

23 December 2025 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
DGDigant Gupta
Digant Gupta
AKAmandeep Kaur
Amandeep Kaur
VVVikas Verma
Vikas Verma
DODésirée A. M. Van Oorschot
Désirée A. M. Van Oorschot
YPYolanda Penders
Yolanda Penders
AGAdriana Guzman-Holst
Adriana Guzman-Holst
Introduction There is a gap in the understanding of the burden of respiratory syncytial virus (RSV) among adults in low, lower-middle, and upper-middle income countries, particularly with regard to up-to-date epidemiological data. Meta-analyses were conducted to determine pooled estimates of RSV prevalence among high-risk 18–59-year-old adults and ≥ 50-year-old adults with or without risk factors or comorbidities, who present with respiratory illnesses in low, lower-middle, and upper-middle income countries. Methods Using studies identified from a previously described systematic literature review, a random-effects model was used to determine pooled prevalence for each study population. Subgroup analyses and meta-regression were conducted using the moderator variables deemed most relevant a priori and a mixed-effects approach. Results Pooled RSV prevalence estimates were 5.1% (95% confidence interval [CI] 3.9–6.6%) and 3.9% (95% CI 3.3–4.7%) across 33 studies in 18–59-year-old high-risk adults with respiratory illnesses and 66 studies in ≥ 50-year-old adults with respiratory illnesses, respectively. Subgroup analyses for 18–59-year-old high-risk adults found geography, study setting, and respiratory illness to collectively explain ~ 54% of the variation in RSV prevalence estimates. The diagnostic method for RSV was found to explain ~ 8% of the variation in RSV prevalence estimates in ≥ 50-year-old adults; no other factors explored via subgroup analyses for ≥ 50-year-old adults had a notable effect on variation. For both populations, a substantial level of residual heterogeneity was observed using Higgin’s I2 when studies were split for subgroup analyses. Conclusions Overall, there is a considerable disease burden associated with RSV among 18–59-year-old high-risk and ≥ 50-year-old adults with respiratory illnesses in low, lower-middle, and upper-middle income countries, highlighting the need for improved prevention programs for RSV in these populations. Graphical Abstract